Importance of 5-FU-based adjuvant Chemotherapy after preoperative Radio Chemo Threapy in locally advanced Rectal Cancer 10-Year results of the EORTC-22921-Study

被引：1
|
作者：
Guckenberger, Matthias [1 ]
机构：
[1] Univ Hosp Zurich USZ, Dept Radiat Oncol, CH-8091 Zurich, Switzerland
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2014年 / 190卷 / 08期
关键词：
PHASE-III TRIAL; POSTOPERATIVE CHEMORADIOTHERAPY; COLON; CAO/ARO/AIO-94; FLUOROURACIL; OXALIPLATIN; SURVIVAL; THERAPY;
D O I：
10.1007/s00066-014-0699-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：772 / 773
页数：2
相关论文
共 40 条
  • [31] Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer.
    Hong, Yong Sang
    Kim, Sun Young
    Lee, Ji Sung
    Nam, Byung-Ho
    Kim, Jeong Eun
    Kim, Kyu-Pyo
    Park, Joon Oh
    Park, Young Suk
    Baek, Ji Yeon
    Kim, Tae-You
    Lee, Keun-Wook
    Ahn, Joong Bae
    Jung, Kyung Hae
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Differential clinical outcomes after 3 versus 5 years in a comparison of preoperative chemotherapy with and without radiotherapy in locally advanced rectal cancer: A national cohort propensity score-matched study
    Zhang, Yuanxin
    Luo, Rui
    Peng, Jingqi
    He, Zichuan
    Tan, Delin
    Liu, Xueping
    Wang, Hui
    Wang, Huaiming
    HELIYON, 2024, 10 (06)
  • [33] A randomized, open-label, parallel-design phase III study to compare adjuvant 5-FU plus oxaliplatin (mFLOX) versus observation in locally advanced rectal cancer after neoadjuvant chemoradiation
    Braghiroli, M. I.
    Moniz, C. M. V.
    Riechelmann, R. S. P.
    Dornellas, A. F. L.
    Caparelli, F.
    Alban, L.
    Alex, A.
    Bariani, G. M.
    Senna Leite, L. A.
    Giollo Rivelli, T.
    Nebuloni, D.
    Ortega, C.
    Braghiroli, O. F. M.
    Moutinho, K.
    Nahas, S.
    Nahas, C.
    Cotti, G.
    Sabbaga, J.
    Ceconello, I.
    Hoff, P. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S416 - S416
  • [34] Neo-adjuvant chemotherapy in locally advanced beast cancer (LABC): FEC (5FU, epirubicin, cyclophosphamlde) vs high dose intensity EC+G-CSF (filgrastim). An EORTC-NCIC-SAKK study. Preliminary results of dose intensity (DI)
    Therasse, R
    Tsitsa, C
    Sahmoud, T
    Tomiak, E
    Goldhirsch, A
    Piccart, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 372 - 372
  • [35] Intergroup 0144 a phase III rectal surgical adjuvant study of pelvic radiation (XRT) plus 5-FU based chemotherapy (bolus 5-FU before and after PVI plus XRT vs PVT before, during, and after XRT vs biochemically modulated bolus 5-FU and XRT): Mature outcome results and pelvic failure analysis
    Smalley, SR
    Benedetti, J
    Williamson, S
    Robertson, J
    Fisher, B
    Martenson, J
    Benson, A
    Mayer, R
    Cripps, C
    Estes, N
    MacDonald, J
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S137 - S138
  • [36] Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients:: 10-year follow-up results of the French Adjuvant Study Group 01 trial
    Fumoleau, P
    Kerbrat, P
    Romestaing, P
    Fargeot, P
    Brémond, A
    Namer, M
    Schraub, S
    Gaudier, MJ
    Mihura, J
    Monnier, A
    Clavère, P
    Serin, D
    Seffert, P
    Pourny, C
    Facchini, T
    Jacquin, JP
    Sztermer, JF
    Datchary, J
    Ramos, R
    Luporsi, E
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 298 - 305
  • [37] Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
    Roedel, Claus
    Graeven, Ullrich
    Fietkau, Rainer
    Hohenberger, Werner
    Hothorn, Torsten
    Arnold, Dirk
    Hofheinz, Ralf-Dieter
    Ghadimi, Michael
    Wolff, Hendrik A.
    Lang-Welzenbach, Marga
    Raab, Hans-Rudolf
    Wittekind, Christian
    Stroebel, Philipp
    Staib, Ludger
    Wilhelm, Martin
    Grabenbauer, Gerhard G.
    Manns, Hans Hoff
    Lindemann, Fritz
    Schlenska-Lange, Anke
    Folprecht, Gunnar
    Sauer, Rolf
    Liersch, Torsten
    Sauer, R.
    Hohenberger, W.
    Fietkau, R.
    Lahmer, G.
    Golcher, H.
    Klautke, G.
    Hartmann, A.
    Rau, T.
    Keilholz, L.
    Henneking, K.
    Muehldorfer, S.
    Klein, S.
    Stolte, M.
    Staar, S.
    Lehnert, T.
    Hertenstein, B.
    Freys, S. M.
    Pflueger, K.-H.
    Sendt, W.
    Teyssen, S.
    Latz, D.
    Leibl, B. J.
    Matek, W.
    Grabenbauer, G. G.
    Alfrink, M.
    Kreczy, A.
    Strobel, G. F.
    Düwel, H.-J.
    LANCET ONCOLOGY, 2015, 16 (08): : 979 - 989
  • [38] Disease-free survival improvement with an epirubicin-based chemotherapy in poor prognosis, node-negative breast cancer patients: 10-year follow-up results of French Adjuvant Study Group 03 trial
    Hery, M
    Schraub, S
    Bonneterre, J
    Roche, H
    Luporsi, E
    Kerbrat, P
    Fumoleau, P
    Monnier, A
    Fargeot, P
    Goudier, MJ
    Chapelle-Marcillac, I
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S30 - S31
  • [39] Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The ADORE).
    Hong, Yong Sang
    Nam, Byung-Ho
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Park, Joon Oh
    Park, Young Suk
    Kim, Sun Young
    Kim, Tae-You
    Kim, Jee Hyun
    Ahn, Joong Bae
    Jung, Kyung Hae
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Effect of paclitaxel-carboplatin (PC) consolidation chemotherapy after weekly PC concurrent chemo-radiotherapy (CCR) for patients with locally advanced non-small cell lung cancer (LA-NSCLC): 3-year definitive results of the B001-phase III GERCOR-study.
    Colin, P.
    Jovenin, N.
    Ganem, G.
    Duhamel, J.
    Oster, J.
    Guichard, F.
    Cretin, J.
    Terrioux, P.
    Brechot, J.
    Morere, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 392S - 392S
1234